Jennifer Lockridge, PhD

VP, Dicerna TRU Early Development at Novo Nordisk

Speaker

Jennifer Lockridge, Ph.D. has over 25 years of pharmaceutical experience providing strategy and support for preclinical and clinical development programs. She has experience with oligonucleotides in a variety of therapeutic areas supporting Pre-IND through NDA regulatory filings. Jennifer is currently Vice President of Early Development in Global Nucleic Acid Therapies at Novo Nordisk where she leads a multidisciplinary team responsible for moving early siRNA development programs from IND supporting studies through Phase I. Prior to the acquisition of Dicerna by Novo Nordisk in 2021, she was SVP of Program Development at Dicerna Pharmaceuticals where she was responsible for strategy and execution of Dicerna’s internal development programs as well as programs partnered with external collaborators. Before joining Dicerna, she spent nine years consulting with multiple biotech and large pharmaceutical companies to provide direction and support for oligonucleotide development programs. She also spent over ten years working at Sirna Therapeutics, Inc. (formerly Ribozyme Pharmaceuticals, Inc.). Jennifer received her Ph.D. in pharmacology at the Oregon Health Sciences University, Portland, Oregon and pursued postdoctoral training at the FDA’s National Center for Toxicological Research, Jefferson, Arkansas.